BRISTOL-MYERS SQUIBB COMPANY Shipping, Handling and Transportation Costs (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Shipping, Handling and Transportation Costs (Deprecated 2018-01-31) of $70.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShippingHandlingAndTransportationCosts · last filed 2017-02-21
- BRISTOL-MYERS SQUIBB COMPANY shipping, handling and transportation costs (deprecated 2018-01-31) for fiscal 2016 was $70.00M, a 17.65% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY shipping, handling and transportation costs (deprecated 2018-01-31) for fiscal 2015 was $85.00M, a 26.09% decline from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY shipping, handling and transportation costs (deprecated 2018-01-31) for fiscal 2014 was $115.00M, a 3.36% decline from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY shipping, handling and transportation costs (deprecated 2018-01-31) for fiscal 2013 was $119.00M, a 4.80% decline from fiscal 2012.
| Period end | Shipping, Handling and Transportation Costs (Deprecated 2018-01-31) 12 month |
|---|---|
| 2016-12-31 | $70.00M 10-K · filed 2017-02-21 |
| 2015-12-31 | $85.00M 10-K · filed 2017-02-21 |
| 2014-12-31 | $115.00M 10-K · filed 2017-02-21 |
| 2013-12-31 | $119.00M 10-K · filed 2016-02-12 |
| 2012-12-31 | $125.00M 10-K · filed 2015-02-13 |
| 2011-12-31 | $139.00M 10-K · filed 2014-02-14 |
| 2010-12-31 | $135.00M 10-K · filed 2013-02-15 |
| 2009-12-31 | $208.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |